What Does DOJ’s New Corporate Enforcement Policy Mean for the FDA- and DEA-Regulated Industry? April 23, 2026 By Andrew J. Hull & Anne K. Walsh —

https://www.thefdalawblog.com/2026/04/what-does-dojs-new-corporate-enforcement-policy-mean-for-the-fda-and-dea-regulated-industry/?utm_source=rss&utm_medium=rss&utm_campaign=what-does-dojs-new-corporate-enforcement-policy-mean-for-the-fda-and-dea-regulated-industry It’s been a month since DOJ announced the “first-ever Department-wide corporate enforcement policy” for criminal matters. Touted as a means of “promoting uniformity, predictability, and fairness” in how DOJ pursues white-collar cases against corporate defendants, the new “Corporate Enforcement and Voluntary Self-Disclosure Policy” (CEP) sets a framework for prosecutors deciding whether to bring, and a roadmap for corporate defendants on how to avoid, federal charges. Like the other voluntary self-disclosure policies from various DOJ offices and U.S. Attorney’s Offices throughout the country, the Department-wide CEP seeks to incentivize corporate behavior, voluntary self-reporting of potential misconduct, cooperation with law enforcement, and good faith efforts to rectify wrongdoing.